# Exploring Predictors of Symptoms Relapse After Discontinuation of Treatment in Overactive Bladder (OAB) Patients

> **NCT00730535** · PHASE4 · COMPLETED · sponsor: **KYU-SUNG LEE** · enrollment: 173 (actual)

## Conditions studied

- Overactive Bladder

## Interventions

- **DRUG:** Tolterodine
- **DRUG:** Tolterodine
- **DRUG:** Tolterodine 6

## Key facts

- **NCT ID:** NCT00730535
- **Lead sponsor:** KYU-SUNG LEE
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 173 (ACTUAL)
- **Last updated:** 2019-12-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00730535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00730535, "Exploring Predictors of Symptoms Relapse After Discontinuation of Treatment in Overactive Bladder (OAB) Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00730535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*